JP Morgan Maintains Overweight on Denali Therapeutics, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Denali Therapeutics but lowers the price target from $29 to $28.

October 11, 2024 | 2:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan's analyst Jessica Fye maintains an Overweight rating on Denali Therapeutics but slightly lowers the price target from $29 to $28.
The Overweight rating suggests a positive outlook, but the slight reduction in the price target indicates a minor adjustment in expectations. This could lead to a neutral short-term impact on the stock price as the overall sentiment remains positive.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100